Skip to main content

Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Jefferies Raises PT On Biogen Idec To $120
Joe Young  
 
April 25, 2011 7:47am   Comments
Share:

Jefferies & Company has raised the price target on Biogen Idec (NASDAQ: BIIB) from $100 to $120 and maintains its Buy rating.

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

 

Related Articles (BIIB)

Beyond The Numbers: 8 Analysts Discuss Biogen Stock
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Earnings Scheduled For July 31, 2025
Biogen's Earnings Outlook
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
View Comments and Join the Discussion!

Posted-In: biogen idec Jefferies & CompanyPrice Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com